

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
------------------	----------------

NATURE OF CONVEYANCE:	ASSIGNMENT
-----------------------	------------

CONVEYING PARTY DATA	
Name	Execution Date
Gryphon Therapeutics, Inc.	12/21/2005

RECEIVING PARTY DATA	
Name:	Amylin Pharmaceuticals, Inc.
Street Address:	9360 Towne Centre Drive
City:	San Diego
State/Country:	CALIFORNIA
Postal Code:	92121

PROPERTY NUMBERS Total: 9	
Property Type	Number
Patent Number:	6673347
Application Number:	07043530
Application Number:	07220196
Application Number:	07380738
Application Number:	07506545
Application Number:	07742159
Application Number:	07866262
Application Number:	08089051
Application Number:	10673489

CORRESPONDENCE DATA	
Fax Number:	(858)552-1936
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(858) 552-2200
Email:	ahalverson@amylin.com
Correspondent Name:	Molly A Holman, Ph.D.
Address Line 1:	Amylin Pharmaceuticals, Inc.

CH \$360.00 6673347

Address Line 2: 9360 Towne Centre Drive  
Address Line 4: San Diego, CALIFORNIA 92121

ATTORNEY DOCKET NUMBER: 0904-GY

NAME OF SUBMITTER: Amanda J. Halverson

Total Attachments: 3  
source=04 assignments#page1.tif  
source=04 assignments#page2.tif  
source=04 assignments#page3.tif

**ASSIGNMENT**

WHEREAS, **GRYPHON THERAPEUTICS, INC.**, of 35473 Dumbarton Ct., Newark, CA 94560 (c/o Rose Ryan), formerly of South San Francisco, California, United States of America, a Corporation of the State of California, the undersigned Assignor, hereby states it is the owner of each of the patent applications and patents identified herein and on the attached Exhibit 1 and inventions disclosed therein by virtue of obligations to assign to it by the original inventors or by virtue of Assignments to it by either the original inventors or by the previous owner Gryphon Sciences, of South San Francisco, California, United States of America;

WHEREAS, **AMYLIN PHARMACEUTICALS, INC.**, of San Diego, California, United States of America, a Corporation of the State of Delaware, is desirous of acquiring the entire right, title and interest in and to said invention or inventions and any and all patents to be obtained therefor;

NOW, THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, the receipt of which is hereby acknowledged, **GRYPHON THERAPEUTICS, INC.** does hereby sell, assign and transfer to **AMYLIN PHARMACEUTICALS, INC.**, ("Assignee") its successors and assigns, the entire right, title and interest in and to said application(s), patent(s) and/or invention(s), in any form or embodiment, whether or not listed in Exhibit 1; and in and to any and all applications filed in any country based thereon, whether or not listed in Exhibit 1, including the right to file applications in countries other than the country of priority filing under the provisions of any international convention; also the entire right, title and interest in and to any and all patents, including reissues and extensions thereof, obtained in any country upon said inventions, whether or not listed in Exhibit 1; and to any and all continuing applications, including divisional, continuation and continuation-in-part applications and substitute applications; to all prior applications disclosing said inventions to which said application(s) or patents(s) claim priority, including any not listed in Exhibit 1; and to any other applications claiming the benefit of said prior applications, including any not listed in Exhibit 1.

Notwithstanding the foregoing paragraph, said application(s), patent(s), and/or invention(s) assigned and transferred hereby shall include only Assignor's rights to applications, patents and/or inventions relating directly to CPS Technology as defined in the Purchase Agreement between **GRYPHON THERAPEUTICS, INC.**, and **AMYLIN PHARMACEUTICALS, INC.** dated November 28, 2005 (the "Purchase Agreement"), and shall not include Assignor's rights to applications, patents and/or inventions relating to patent families that are not listed in Schedule 1.1(a) to the Purchase Agreement.

**GRYPHON THERAPEUTICS, INC.** hereby authorizes and requests the issuing authority to issue any and all patents on said application or applications to **AMYLIN**

AND for the same consideration, **GRYPHON THERAPEUTICS, INC.** hereby covenants and agrees to and with **AMYLIN PHARMACEUTICALS, INC.**, its successors, legal representatives and assigns, that **GRYPHON THERAPEUTICS, INC.** will, and, hereby

grants to the **Assignee** the right to enforce the original inventors' obligations to assign their rights to **GRYPHON THERAPEUTICS, INC.** such that consistent with their obligations to assign to **GRYPHON THERAPEUTICS, INC.**, the original inventors will, whenever counsel of the said Assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent, or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said Assignee, its successors, legal representatives and assigns, but at the cost and expense of said Assignee, its successors, legal representatives and assigns.

IN TESTIMONY WHEREOF, **GRYPHON THERAPEUTICS, INC.** has hereto set its hands on the dates set after its signature.

Signature: *F. Blobel* Date: 12/21/05

Friedhelm Blobel


CEO and President

Gryphon Therapeutics, Inc.

State of California )  
                                  )  
County of San Mateo) ss.

On this 21 day of December, 2005, before me, Sylvia Rogers  
Notary Public, personally appeared Friedhelm Blobel, personally known  
to me or proved to me on the basis of satisfactory evidence to be the person who executed  
the foregoing instrument and acknowledged that he/~~she~~ executed the same as his/~~her~~ free  
act and deed; in testimony whereof I have hereto set my hand and official seal on the day  
last above written.

*Sylvia Rogers*



**Exhibit 1**

Application or Patent No. (US and foreign)	Filing Date or Issuance Date	Country	Gryphon Docket Number	Issue Date	Patent	USPTO Recorded Prior Assignment to Gryphon Sciences (Reel/Frame)	USPTO Recorded Prior Assignment to Gryphon Therapeutics (Reel/Frame)
8610551	4/30/1986	UNITED KINGDOM	004/00GB-A				
87106113.1	4/28/1987	EUROPEAN PATENT	004/00EP	9/27/1995	0243929		
07/043530	4/28/1987	UNITED STATES	004/00US-B				
535,860	4/29/1987	CANADA	004/00CA	7/18/2000	1,341,053		
107898/87	4/30/1987	JAPAN	004/00JP	6/14/1996	2528464		
46752/96	4/30/1987	JAPAN	004/01JP	3/19/1999	2900992		
07/220,196	7/18/1988	UNITED STATES	004/00US-C			Reel: 013292 Frame: 0030	Reel: 014074 Frame: 0965
07/380,738	7/17/1989	UNITED STATES	004/00US-D			Reel: 013292 Frame: 0030	Reel: 014074 Frame: 0965
07/506,545	4/5/1990	UNITED STATES	004/00US-E			Reel: 013292 Frame: 0030	Reel: 014074 Frame: 0965
07/742,159	8/1/1991	UNITED STATES	004/00US-F			Reel: 013292 Frame: 0030	Reel: 014074 Frame: 0965
07/866,262	4/10/1992	UNITED STATES	004/00US-G			Reel: 013292 Frame: 0030	Reel: 014074 Frame: 0965
08/089,051	8/6/1993	UNITED STATES	004/00US				
08/241,687	5/15/1994	UNITED STATES	004/01US	1/6/2004	6,673,347	Reel: 013292 Frame: 0030	Reel: 014074 Frame: 0965
10/673,489	9/30/2003	UNITED STATES	004/02US				
0243929	9/27/1995	EUROPEAN PATENT	004/00EP				
1,341,053	7/18/2000	CANADA	004/00CA				
2528464	6/14/1996	JAPAN	004/00JP				
2900992	3/19/1999	JAPAN	004/01JP				
6,673,347	1/6/2004	UNITED STATES	004/01US			Reel: 013292 Frame: 0030	Reel: 014074 Frame: 0965